An RCT of ganciclovir prophylaxis for CMV disease in pediatric liver transplant recipients.

被引：0
|
作者：
King, SM
Superina, R
Andrews, W
Winston, D
Dunn, S
Colombani, P
机构：
[1] HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA
[2] SW MED CTR,DALLAS,TX
[3] UNIV CALIF LOS ANGELES,LOS ANGELES,CA
[4] ST CHRISTOPHERS HOSP,PHILADELPHIA,PA
[5] JOHNS HOPKINS UNIV,BALTIMORE,MD
来源：
CLINICAL INFECTIOUS DISEASES | 1996年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：243 / 243
页数：1
相关论文
共 50 条
  • [21] Comparison of valganciclovir vs. intravenous ganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients
    Clark, BS
    Chang, IF
    Karpen, SJ
    Herrera, L
    Goss, JA
    Scott, JD
    Bristow, LJ
    Quiros-Tejeira, RE
    LIVER TRANSPLANTATION, 2003, 9 (06) : C30 - C30
  • [22] Incidence of CMV with dual therapy prophylaxis in renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Polito, CC
    Buchanan, EP
    Rodwell, D
    Emovon, O
    Afzal, F
    Rogers, J
    Lin, A
    Brown, E
    Baliga, PK
    Rajagopalan, PR
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 780A - 780A
  • [23] Changes in the level of CMV antigenemia (pp65) in liver transplant recipients receiving oral ganciclovir as CMV prophylaxis
    Singh, N
    Yu, VL
    Gayowski, T
    Marino, IR
    TRANSPLANTATION, 1999, 67 (07) : S98 - S98
  • [24] Intravenous versus oral ganciclovir in the prevention of CMV infection and disease in liver transplant recipients
    Bajjoka, I
    Baliad, P
    Brown, K
    May, E
    Escobar, F
    Mozes, M
    Abouljoud, M
    HEPATOLOGY, 1997, 26 (04) : 116 - 116
  • [25] Six months CMV prophylaxis with valgancielovir prevents CMV-induced disease in 96% of kidney transplant recipients.
    Cantarovich, Diego
    Giral, Magali
    Dantal, Jacques
    Blancho, Gilles
    Soulillou, Jean-Paul
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 502 - 502
  • [26] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
  • [27] Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors
    Seu, P
    Winston, DJ
    Holt, CD
    Kaldas, F
    Busuttil, RW
    TRANSPLANTATION, 1997, 64 (11) : 1614 - 1617
  • [28] Increased Incidence of Leucopenia With FDA Approved Valganciclovir Dosing for CMV Prophylaxis in Pediatric Kidney Transplant Recipients.
    Bhatnagar, S.
    Palma, K.
    Palmer, J.
    Baluarte, J.
    Amaral, S.
    TRANSPLANTATION, 2014, 98 : 501 - 501
  • [29] Universal Prophylaxis for Cytomegalovirus Disease in Pediatric Liver Transplant Recipients
    Gautier, S.
    Tsirulnikova, O.
    Zhilkin, I.
    Akhaladze, D.
    Tsirulnikova, I.
    Chekletsova, E.
    TRANSPLANTATION, 2016, 100 : S202 - S202
  • [30] Comparison of valganciclovir and oral ganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.
    Kraman, AA
    Hardwick, LL
    Filo, RS
    Govani, MV
    Milgrom, ML
    Tector, AJ
    Pescovitz, MD
    PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
12345